Key Takeaways
Retractable Technologies, Inc. (RVP) reported a 13.5 percent drop in first-quarter sales to $7.2 million and a wider operating loss, as a shift in product mix and persistent tariffs weighed on pricing.
The company attributed the revenue decline primarily to a 19.9% fall in domestic sales, which occurred despite a 3.6% increase in overall unit sales. A higher proportion of lower-priced international sales, particularly of its EasyPoint needles, dragged on the top line. International revenue grew 42.4% in the quarter.
The Little Elm, Texas-based medical device maker posted a net loss of $4.2 million, or 14 cents per share. This was a narrower loss than the $10.5 million, or 35 cents per share, reported in the first quarter of 2025, a period that included a $7.2 million unrealized loss on investments. Shares of Retractable have fallen 3.8% since the May 21 report.
The company’s domestic revenue fell disproportionately to unit sales due to changes in product mix and higher costs tied to distributor agreements. Syringes accounted for 80.8% of sales. The company warned that tariffs on products imported from China, which were subject to a 110% rate as of May 1, 2026, could continue to materially affect costs. In the first quarter, 61% of sourced products came from Chinese manufacturers.
To mitigate these costs, Retractable has focused on expanding its domestic production. The company manufactured 39% of its products domestically in the first quarter and is adapting equipment to produce 0.5mL syringes in commercial quantities in the second half of 2026.
In April 2026, Retractable reduced its workforce by approximately 16%, a move expected to generate about $2.2 million in annual savings. The company said 58% of the reductions were in manufacturing roles, with the rest in sales and support. Operating expenses in the quarter rose 14% to $5.3 million, though this included about $900,000 in non-recurring consulting expenses and charitable product donations.
The guidance from Retractable’s management suggests that liquidity may decline over the next one to three years due to tariffs and the costs of increasing domestic manufacturing. However, the company believes its current cash of $2.8 million and $32.9 million in debt and equity securities are sufficient to meet its needs. Investors will be watching for progress on the domestic production ramp-up in the second half of the year.
This article is for informational purposes only and does not constitute investment advice.
